BLAINTRAVENOUS, SUBCUTANEOUSINJECTABLE2 Generics Approved
Approved
Oct 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ACTEMRA (tocilizumab) by Roche is interleukin 6 receptor antagonists [moa]. Approved for interleukin-6 receptor antagonist [epc]. First approved in 2013.
Drug data last refreshed Yesterday
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Started Dec 2025
78 enrolled
Giant Cell Arteritis (GCA)
RCT of Tocilizumab for Anti-MDA5+DM
Started Nov 2025
110 enrolled
Dermatomyositis
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Started Oct 2025
60 enrolled
Acute Hypoxemic Respiratory Failure
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Started Jul 2024
168 enrolled
Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer
Real World Use of Tocilizumab Biosimilar studY
Started Mar 2024
600 enrolled
Rheumatoid Arthritis
Worked on ACTEMRA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.